logo-loader

AstraZeneca ovarian cancer drug approved for wider use

Published: 07:35 18 Aug 2017 BST

ovarian
The US Food & Drug Administration also agreed a switch to two-tablets a day

American regulators have given the green light for the wider usage of an ovarian cancer drug.

Sold by AstraZeneca PLC (LON:AZN) and Merck & Co Inc (NYSE:MRK), Lynparza will now be prescribed to patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

The US Food & Drug Administration also agreed a switch to two-tablets a day from the current eight capsules regimen.

Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy.

PARP inhibitor 

It is one of a class of drugs called PARP inhibitors which prevent cancer cells from repairing damaged DNA, causing them to die.

"Physicians have almost three years of clinical experience with Lynparza on the market and we are now pleased to bring this important medicine, in a new tablet formulation, to a broader group of women,” said AZ’s Sean Bohen.

“[The] approvals validate more than 10 years of dedicated research behind Lynparza, the world's first PARP inhibitor, which now provides oncologists with the greater flexibility for use in terms of treatment settings.

“It builds on our recently-announced collaboration with Merck, which aims to further increase the number of treatment options available to patients."

Researchers are assessing the potential of using Lynparza to treat pancreatic and prostate cancer.

FTSE starts flat, Unilever jumps on ice cream overhaul - Market Report

The FTSE 100 has opened flat, with the largest gain coming from multinational consumer goods heavyweight Unilever. The company lifted more than 5% in early trading after launching plans to sack 7,500 workers as part of an overhaul of its ice cream business. Over in the pharmaceutical...

46 minutes ago